MRD Could Take Center Stage in Pediatric and Adult ALL Paradigms
Published: Thursday, Jun 27, 2019
Jerald P. Radich, MD
There are several ways to assess minimal residual disease (MRD) in patients with acute lymphoblastic leukemia (ALL), explained Jerald P. Radich, MD. And although there is some debate as to whether it should be termed “minimal” or “measurable,” it may become standard practice to test for MRD as a surrogate endpoint in clinical trials.
... to read the full story